Needham downgraded GW Pharmaceuticals from Buy to Hold
Save time and jump to the most important pieces.
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)
15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold
Citigroup downgraded GW Pharmaceuticals from Buy to Neutral
HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl
LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the
Jazz Pharmaceuticals (NASDAQ:JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYSE:TEVA), Apotex, Alkem and several other generic drugmakers alleging patent infringement on the cannabis-derived therapy. Epidiolex, which won its U.S. Food and Drug Administration (FDA) approval in 2018 and 2020 as the first therapy comprised of an active ingredient derived from cannabis, treats seizures from Lennox-Gastaut Syndrome (“LGS”), Dravet Syndrome (“DS”), and Tuberous Sclerosis Complex (“TSC”), all of which are rare diseases characterized by severe early-onset epilepsy. What Happened According to the lawsuit, filed
Epileptic seizure frequency fell by an average of 86% among ten children treated with whole-plant medicinal cannabis, reveals a case series published in the open-access journal BMJ Paediatrics Open. None of the children had responded to other treatments, including the only cannabidiol (CBD) product licensed for their condition, reported medicalexpress.com Prompted by parents whose children had responded well to whole plant medicinal cannabis extracts, but not to conventional antiepileptic drugs or purified cannabidiol (CBD oil), medicinal (whole plant) cannabis was designated a prescription medicine for the treatment of severe childhood epilepsy in 2018. Whole plant cannabis includes THC,
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical. Mentioned in today's commentary includes: Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR